This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies sold 238,243 shares of Viridian Therapeutics, an estimated $7.08 million trade based on average closing prices from January through March 2026. The article is a factual disclosure of a sizable share sale, with limited immediate fundamental implications. Market impact is likely modest and mainly relevant for positioning and sentiment around the stock.

Analysis

HighVista Strategies sold 238,243 shares of Viridian Therapeutics, an estimated $7.08 million trade based on average closing prices from January through March 2026. The article is a factual disclosure of a sizable share sale, with limited immediate fundamental implications. Market impact is likely modest and mainly relevant for positioning and sentiment around the stock.